Apollomics Inc.
APLM Nasdaq· Pharmaceutical Preparations
KIRA · Stoqly’s AI analyst, in plain words
- Apollomics Inc. had $8.5M of revenue in fiscal 2025.
- Apollomics Inc. lost $10.9M in fiscal 2025.
- Apollomics Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 41.8%.
- Apollomics Inc. has $3.3M more cash than debt.
Market cap
—
P/E
—
Revenue
$8.5M
Net income
−$10.9M
Free cash flow
—
Operating margin
—
Apollomics Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−128.7%
No. It lost money last year.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
What Apollomics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 24, 2026
- Legal name
- Apollomics Inc.
- CIK
- 0001944885
Apollomics Inc. · APLM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $8.5M |
| Net income | −$94.8M | −$241M | −$173M | −$53.9M | −$10.9M |
| Net margin | — | — | — | — | −128.7% |
| Diluted EPS | −$3.37 | −$844.95 | −$231.99 | −$52.80 | −$7.57 |
| Cash | |||||
| Cash from operations | −$43.3M | −$42.8M | −$43.2M | −$28.7M | −$10.4M |
| Capital expenditure | $0.1M | $0.4M | $0.0M | $0.0M | — |
| Free cash flow | −$43.4M | −$43.2M | −$43.2M | −$28.8M | — |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | −92.2% | −99.0% | 161.1% | 37.1% | 41.8% |
| Debt and strength | |||||
| Cash and short-term investments | $46.7M | $32.7M | $32.1M | $9.8M | $3.3M |
| Debt incl. finance leases | — | — | $4.2M | $0.0M | $0.0M |
| Shareholders' equity | −$213M | −$448M | $41.2M | $4.9M | −$3.2M |
| Current ratio | 7.3x | 4.5x | 2.9x | 1.4x | 1.0x |
| Interest coverage | — | 10.5x | — | — | — |
| Returns and quality | |||||
| Return on equity | — | — | — | −233.7% | −1,305.4% |
| Return on tangible equity | — | — | −651.9% | −1,722.4% | — |
| Piotroski F-score | — | 2 | 2 | 2 | 3 |
| Altman Z'' | — | −17.5 | — | — | — |
Insiders bought, 12 months
$8.3M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Apollomics Inc. · APLM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001944885). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.